An Australian stem cell and regenerative medicine company

ASX Announcements

28 Mar 2018 Cleansing Notice
28 Mar 2018 Appendix 3B-Exercise of Options
27 Mar 2018 FDA Grants Orphan Drug Designation to Cynata for CYP-001
13 Mar 2018 Cleansing Notice
13 Mar 2018 Appendix 3B-Exercise of Options
12 Mar 2018 Updated Top 20 Shareholders
11 Mar 2018 Shaw and Partners Updates Cynata Research Coverage
28 Feb 2018 Cleansing Notice
28 Feb 2018 Appendix 3B-Exercise of Options
26 Feb 2018 Excellent Data from Final Preliminary Evaluation Period
04 Feb 2018 Cynata Engineered MSC Study Review Reveals Promising Results
30 Jan 2018 December 2017 Quarterly Report
23 Jan 2018 Cynata Treats First Patient in Cohort B
22 Jan 2018 Cynata & Celularity Inc Execute MOU
22 Jan 2018 Lapse of Unlisted Options
22 Jan 2018 Encouraging Early Data-Cynata Clinical Trial Proceeds
11 Jan 2018 Release of Securities from Voluntary Escrow
11 Jan 2018 Interview with Cynata Co-Founder Professor Slukvin
17 Dec 2017 End of Year Newsletter & 2018 Outlook
14 Dec 2017 Cynata Receives $1.3m R&D Tax Incentive Refund
11 Dec 2017 Final Preclinical Asthma Study Confirms Efficacy
07 Dec 2017 United States Patent Allowance for Core Cynata Technology
20 Nov 2017 Appendix 3Y-Paul Wotton
20 Nov 2017 Appendix 3B
17 Nov 2017 Results of Annual General Meeting
17 Nov 2017 Managing Director's Annual General Meeting Presentation
17 Nov 2017 Chairman's Annual General Meeting Address
14 Nov 2017 Company Investor Presentation
14 Nov 2017 Enrolment Completed in 1st Cohort of Cynata Clinical Trial
27 Oct 2017 September 2017 Quarterly Report
10 Oct 2017 Van Leeuwenhoeck Institute Updates Cynata Research Coverage
09 Oct 2017 Annual Report to Shareholders
09 Oct 2017 Notice of Annual General Meeting/Proxy Form
09 Oct 2017 Cynata to Increase Exposure in Japan
27 Sep 2017 US Patent Granted for Cynata Cymerus Technology
10 Sep 2017 HC Wainwright & Co Updates Cynata Research Coverage
31 Aug 2017 Health Canada Meeting Advances CYP Global Development Plans
24 Aug 2017 Appendix 4G
24 Aug 2017 Appendix 4E & Financial Statements
23 Aug 2017 Positive Data from CYP MSCs in 2nd Preclinical Asthma Study
07 Aug 2017 Appendix 3B
28 Jul 2017 June 2017 Quarterly Report
24 Jul 2017 NDF's Stuart Roberts Initiates Cynata Research Coverage
04 Jul 2017 FDA Meeting Provides Clear Path for US Development Plans
04 Jul 2017 Change of Address
27 Jun 2017 Cynata Therapeutics GvHD Clinical Trial & Corporate Progress
22 Jun 2017 CYP MSC Data in Asthma Model Published in Scientific Journal
20 Jun 2017 Cynata Files New Patent Application for Cymerus in Oncology
19 Jun 2017 United States Patent for Core Cynata Technology
06 Jun 2017 Van Leeuwenhoeck Institute Initiates CYP Research Coverage